Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis

Diabetes

Volumn 65, Issue 6, 2016, Pages 1714-1723

  Cameron Vendrig, Alison ^a,b,c,d,e   Reheman, Adili ^e   Siraj, M Ahsan ^c   Xu, Xiaohong Ruby ^a,b,e   Wang, Yiming ^a,e   Lei, Xi ^e   Afroze, Talat ^b,c,d   Shikatani, Eric ^a,b,c   El Mounayri, Omar ^b,c,d   Noyan, Hossein ^b,c,d   Weissleder, Ralph ^f,g   Ni, Heyu ^a,b,e,h   Husain, Mansoor ^a,b,c,d,i  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e ST MICHAEL'S HOSPITAL   (Canada)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h CANADIAN BLOOD SERVICES   (Canada)

ⁱ UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; CYCLIC AMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; THROMBIN; ANTITHROMBOCYTIC AGENT; GLUCAGON LIKE PEPTIDE 1; PEPTIDE; VENOM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOTTING; BONE MARROW TRANSPLANTATION; CELL CLONING; HUMAN; HUMAN CELL; MALE; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE AGGREGATION; THROMBOSIS; THROMBOSIS PREVENTION; AGONISTS; ANIMAL; CELL LINE; DEFICIENCY; DRUG EFFECTS; LUNG; METABOLISM; PANCREAS;

ANIMALS; CELL LINE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HUMANS; LUNG; MICE; NITRIC OXIDE SYNTHASE TYPE III; PANCREAS; PEPTIDES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOSIS; VENOMS;

EID: 84969776766     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1141     Document Type: Article

References (50)

1. Vinik AI, Erbas T, Park TS, Nolan R, Pittenger GL. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001;24:1476-1485
2. Hou Y, Carrim N, Wang Y, Gallant RC, Marshall A, Ni H. Platelets in hemostasis and thrombosis: novel mechanisms of fibrinogen-independent platelet aggregation and fibronectin-mediated protein wave of hemostasis. J Biomed Res. 30 October 2015 [Epub ahead of print]. DOI: 10.7555/JBR.29.20150121
3. Festa A, D'Agostino R Jr, Mykkänen L, et al.; The Insulin Resistance Atherosclerosis Study (IRAS). Relative contribution of insulin and its precursors to fibrinogen and PAI-1 in a large population with different states of glucose tolerance. Arterioscler Thromb Vasc Biol 1999;19:562-568
4. Ni H. The platelet "sugar high" in diabetes. Blood 2012;119:5949-5951
5. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005;54:2430-2435
6. Mylotte D, Kavanagh GF, Peace AJ, et al. Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets 2012;23:439-446
7. Angiolillo DJ, Bernardo E, Sabaté M, et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 2007;50:1541-1547
8. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-2128
9. Gerstein HC, Miller ME, Genuth S, et al.; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011;364:818-828
10. Scirica BM, Bhatt DL, Braunwald E, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-1326
11. White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-1335
12. Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-242
13. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2014;16:38-47
14. Frederich R, Alexander JH, Fiedorek FT, et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med 2010;122:16-27
15. Engel SS, Golm GT, Shapiro D, Davies MJ, Kaufman KD, Goldstein BJ. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol 2013;12:3
16. Monami M, Dicembrini I, Nardini C, Fiordelli I, Mannucci E. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a metanalysis of randomised clinical trials. Diabetes Obes Metab 2014;16:38-47
17. Gupta AK, Verma AK, Kailashiya J, Singh SK, Kumar N. Sitagliptin: antiplatelet effect in diabetes and healthy volunteers. Platelets 2012;23:565-570
18. Randriamboavonjy V, Fleming I. Endothelial nitric oxide synthase (eNOS) in platelets: how is it regulated and what is it doing there? Pharmacol Rep 2005;57(Suppl.):59-65
19. Naseem KM, Riba R. Unresolved roles of platelet nitric oxide synthase. J Thromb Haemost 2008;6:10-19
20. Ding L, Zhang J. Glucagon-like peptide-1 activates endothelial nitric oxide synthase in human umbilical vein endothelial cells. Acta Pharmacol Sin 2012;33:75-81
21. Erdogdu O, Nathanson D, Sjöholm A, Nyström T, Zhang Q. Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-, PKA- and PI3K/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 2010;325:26-35
22. Clardy SM, Keliher EJ, Mohan JF, et al. Fluorescent exendin-4 derivatives for pancreatic β-cell analysis. Bioconjug Chem 2014;25:171-177
23. Reiner T, Thurber G, Gaglia J, et al. Accurate measurement of pancreatic islet beta-cell mass using a second-generation fluorescent exendin-4 analog. Proc Natl Acad Sci USA 2011;108:12815-12820
24. Gupta NA, Mells J, Dunham RM, et al. Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. Hepatology 2010;51:1584-1592
25. Yang H, Reheman A, Chen P, et al. Fibrinogen and von Willebrand factor-independent platelet aggregation in vitro and in vivo. J Thromb Haemost 2006;4:2230-2237
26. Reheman A, Yang H, Zhu G, et al. Plasma fibronectin depletion enhances platelet aggregation and thrombus formation in mice lacking fibrinogen and von Willebrand factor. Blood 2009;113:1809-1817
27. Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. J Clin Invest 2000;106:385-392
28. Scrocchi LA, Brown TJ, MaClusky N, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996;2:1254-1258
29. Goto H, Nomiyama T, Mita T, et al. Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 2011;405:79-84
30. Arakawa M, Mita T, Azuma K, et al. Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4. Diabetes 2010;59:1030-1037
31. Lei X, Reheman A, Hou Y, et al. Anfibatide, a novel GPIb complex antagonist, inhibits platelet adhesion and thrombus formation in vitro and in vivo in murine models of thrombosis. Thromb Haemost 2014;111:279-289
32. Wang Y, Reheman A, Spring CM, et al. Plasma fibronectin supports hemostasis and regulates thrombosis. J Clin Invest 2014;124:4281-4293
33. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor - or not? Endocrinology 2013;154:4-8
34. Peyot ML, Gray JP, Lamontagne J, et al. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PLoS One 2009;4:e6221
35. Ramos LS, Zippin JH, Kamenetsky M, Buck J, Levin LR. Glucose and GLP-1 stimulate cAMP production via distinct adenylyl cyclases in INS-1E insulinoma cells. J Gen Physiol 2008;132:329-338
36. Practical-Haemostasis.com. Platelet function testing: light transmission aggregometry [LTA] [article online], 2012. Available from http://www.practicalhaemostasis.com/Platelets/platelet-function-testing-lta.html. 17 May 2015
37. Stolla MC, Li D, Lu L, Woulfe DS. Enhanced platelet activity and thrombosis in a murine model of type I diabetes are partially insulin-like growth factor 1-dependent and phosphoinositide 3-kinase-dependent. J Thromb Haemost 2013;11:919-929
38. Sélley E, Kun S, Szijártó IA, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol 2014;13:69
39. Dandona P, Chaudhuri A, Dhindsa S. A novel antihypertensive effect of exenatide, a GLP-1 agonist. Am J Hypertens 2010;23:228
40. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013;15:112-120
41. Pfeffer MA, Claggett B, Diaz R, et al.; ELIXA Investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-2257
42. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013;154:127-139
43. Gambaryan S, Kobsar A, Hartmann S, et al. NO-synthase-/NO-independent regulation of human and murine platelet soluble guanylyl cyclase activity. J Thromb Haemost 2008;6:1376-1384
44. Raslan Z, Aburima A, Naseem KM. The spatiotemporal regulation of cAMP signaling in blood platelets-old friends and new players. Front Pharmacol 2015;6:266
45. Beck F, Geiger J, Gambaryan S, et al. Time-resolved characterization of cAMP/PKA-dependent signaling reveals that platelet inhibition is a concerted process involving multiple signaling pathways. Blood 2014;123:e1-e10
46. Alexopoulos D, Xanthopoulou I, Tsigkas G, et al. Intrinsic platelet reactivity and thrombus burden in patients with ST-elevation myocardial infarction. Thromb Res 2013;131:333-337
47. Lievens D, von Hundelshausen P. Platelets in atherosclerosis. Thromb Haemost 2011;106:827-838
48. Lievens D, Zernecke A, Seijkens T, et al. Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 2010;116:4317-4327
49. Murphy AJ, Bijl N, Yvan-Charvet L, et al. Cholesterol efflux in megakaryocyte progenitors suppresses platelet production and thrombocytosis. Nat Med 2013;19:586-594
50. Kodera R, Shikata K, Kataoka HU, et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011;54:965-978